Pfizer Inc. (NYSE:PFE) Receives $46.53 Average Price Target from Analysts

Pfizer Inc. (NYSE:PFE) has been assigned a consensus recommendation of “Hold” from the twenty-one brokerages that are presently covering the firm, Marketbeat reports. Thirteen research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $46.53.

PFE has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, April 3rd. Credit Suisse Group restated a “buy” rating and set a $48.00 price objective on shares of Pfizer in a research note on Monday, June 17th. Goldman Sachs Group restated a “buy” rating and set a $49.00 price objective on shares of Pfizer in a research note on Monday, June 17th. Bank of America lifted their price objective on shares of Pfizer from $45.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Finally, JPMorgan Chase & Co. restated a “hold” rating and set a $46.00 price objective on shares of Pfizer in a research note on Monday, June 17th.

Shares of PFE traded down $0.77 during midday trading on Wednesday, hitting $42.99. 37,954,458 shares of the stock traded hands, compared to its average volume of 23,895,869. Pfizer has a 1-year low of $36.00 and a 1-year high of $46.47. The company has a market capitalization of $242.91 billion, a price-to-earnings ratio of 14.33, a PEG ratio of 2.54 and a beta of 0.65. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.54 and a quick ratio of 1.27. The company’s 50 day simple moving average is $42.22.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.10. Pfizer had a net margin of 21.31% and a return on equity of 27.48%. The company had revenue of $13.12 billion during the quarter, compared to the consensus estimate of $13.01 billion. During the same quarter in the previous year, the company posted $0.77 earnings per share. The company’s revenue for the quarter was up 1.6% compared to the same quarter last year. As a group, equities analysts forecast that Pfizer will post 2.88 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, June 7th. Shareholders of record on Friday, May 10th were given a $0.36 dividend. This represents a $1.44 annualized dividend and a yield of 3.35%. The ex-dividend date of this dividend was Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.

In related news, insider Alexander R. Mackenzie sold 15,000 shares of Pfizer stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $42.83, for a total value of $642,450.00. Following the transaction, the insider now owns 124,994 shares of the company’s stock, valued at approximately $5,353,493.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Pfizer Inc purchased 50,000 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The stock was bought at an average cost of $17.00 per share, for a total transaction of $850,000.00. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Timber Hill LLC purchased a new stake in Pfizer during the third quarter valued at approximately $2,805,000. South Texas Money Management Ltd. raised its holdings in shares of Pfizer by 2.4% in the third quarter. South Texas Money Management Ltd. now owns 56,785 shares of the biopharmaceutical company’s stock worth $2,503,000 after buying an additional 1,337 shares during the last quarter. Alliancebernstein L.P. raised its holdings in shares of Pfizer by 5.2% in the third quarter. Alliancebernstein L.P. now owns 22,856,459 shares of the biopharmaceutical company’s stock worth $1,007,284,000 after buying an additional 1,133,623 shares during the last quarter. AXA raised its holdings in shares of Pfizer by 6.7% in the third quarter. AXA now owns 2,366,041 shares of the biopharmaceutical company’s stock worth $104,272,000 after buying an additional 149,267 shares during the last quarter. Finally, Rational Advisors LLC raised its holdings in shares of Pfizer by 64.2% in the third quarter. Rational Advisors LLC now owns 11,175 shares of the biopharmaceutical company’s stock worth $492,000 after buying an additional 4,369 shares during the last quarter. 71.83% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: Risk Tolerance

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.